Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DR26FCRJ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,980
Award facts
- Contract value 100% obligated
- $13,979.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $13,979.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 300 mg/2 mL Xolair (omalizumab) auto-injector units. The delivery order, issued on November 14, 2025, with an ultimate completion date of December 8, 2025, carries no set-aside designation, indicating the award was made through open competition. DMS Pharmaceutical Group was selected as the awardee based on its established capability to supply specialized biologic pharmaceuticals and medical consumables to Department of Defense healthcare facilities.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The parent IDC, designated SPE2DR, was awarded to DMS Pharmaceutical Group on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, positioning the company as a regional prime vendor contractor capable of supplying a comprehensive range of pharmaceuticals, biologics, and medical consumables to support global Department of Defense military healthcare operations. The delivery order for Xolair, a biologic immunosuppressant used in treating allergic conditions, exemplifies the company's role in fulfilling specialized pharmaceutical requirements across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRJ4?
SPE2DR26FCRJ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FCRJ4 worth?
The government has obligated $13,980 on SPE2DR26FCRJ4.
Is contract SPE2DR26FCRJ4 an order under another contract?
Yes. SPE2DR26FCRJ4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRJ4 competed?
The extent of competition for SPE2DR26FCRJ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award